Citations

Clear

50 citation(s) found for "Gilbert, Mark R".

ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001
Deshmukh, Snehal, Brown, Paul D. , Gondi, Vinai , Benzinger, Tammy, Devisetty, Kiran , Shah, Sunjay, Usuki, Kenneth Y., Baschnagel, Andrew, Yoon, Harold, Li, Jing , Kachnic, Lisa A. , Armstrong, Terri S. , Benzinger, T., Gilbert, Mark R. , Tomé, Wolfgang A. , Wefel, Jeffrey S. , Bruner, Deborah Watkins , Roberge, David , Kundapur, Vijayananda , Baschnagel, Andrew, Stea, Baldassarre , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi24-vi25

10.1093/neuonc/noz175.092 Get It

Abstract BACKGROUND NRG-CC001 sought to evaluate the neuro-protective effects of avoiding the peri-hippocampal stem cell niche using intensity-modulated radiotherapy during WBRT. METHODS Patients with brain metastasis were stratified by RPA class and prior radiosurgery/surgery and randomized to WBRT+M or HA-WBRT+ Memantine (M) (30Gy in 10 fractions). Standardized NCF tests and the M.D. Anderson Symptom Inventory Brain Tumor (MDASI-BT) were obtained at baseline, 2, 4, 6, and 12 months (mos). The primary endpoint was NCF failure defined using the reliable change index. Pre-specified secondary endpoints included patient-reported symptoms using the MDASI-BT. Time to NCF was reported as cumulative incidence (with death without NCF failure as a competing risk); between-arms differences were tested using Gray’s test. Deterioration at discrete time-points were tested using chi-square tests. MDASI-BT symptom burden, interference, and cognitive and neurologic burden were analyzed using mixed effects models and t-tests within the model using Hochberg’s multiplicity adjustment. RESULTS A total of 518 patients were randomized from 7/2016 to 3/2018. Median follow-up for alive patients was 12.1 mos, with no difference between arms in terms of toxicity, overall survival or intracranial progression-free survival. HA-WBRT+M was associated with lower risk of NCF failure (adjusted HR=0.739, 95% CI: 0.577–0.945, p=0.0.016), with differences first noted at 4 mos in Trail Making Test Part-B (23.3% vs. 40.4% deteriorated, p=0.012). Age did not dilute treatment effect. HA-WBRT+M was associated with reduced cognitive symptom burden in an imputed model (estimate=-0.29, p=0.0425), and also reduced overall symptom burden (p< 0.0001) and interference (p< 0.0016) at 6 mos. CONCLUSIONS The addition of HA to WBRT+M preserved NCF and reduced patient reported cognitive symptom burden, overall symptom burden and symptom interference and should be considered standard of care for any patient fit enough to have WBRT. Supported by grants UG1CA189867 (NCORP), U10CA180868 (NRG Oncology Operations), DCP from the National Cancer Institute.
Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).
Chang, Susan M. , Cairncross, J. Gregory , Bahary, Jean-Paul , Dolinskas, Carol A., Aldape, Kenneth , Schiff, David , Jaeckle, Kurt A. , Brown, Paul D. , Barger, Geoffrey, Werner‐Wasik, Maria, Brachman, David, Peñas-Prado, Marta , Robins, H. Ian, Bélanger, Karl, Schultz, Christopher J. , Zhang, Peixin, Gilbert, Mark R. , Chakravarti, Arnab , Shih, Helen A. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2002-2002

10.1200/jco.2015.33.15_suppl.2002 Get It

Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
Buckner, Jan C. , Pugh, Stephanie L. , Shaw, Edward G. , Barger, Geoffrey, Coons, Stephen W., Ricci, Peter E. , Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , Brachman, David, Schultz, Christopher J. , Bahary, Jean-Paul , Fisher, Barbara J., Kim, Harold , Murtha, Albert , Curran, Walter J. , Gilbert, Mark R. , Suh, John H. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2000-2000

10.1200/jco.2014.32.15_suppl.2000 Get It

NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001
Gondi, Vinai , Pugh, Stephanie L. , Brown, Paul D. , Bovi, Joseph , Benzinger, Tammie, Khuntia, Deepak , Grosshans, David R. , Konski, André , Robidoux, André, Devisetty, Kiran , Shah, Sunjay, Usuki, Kenneth Y., Anderson, Bethany , Yoon, Harold, Li, Jing , Chmura, Steven J. , Kachnic, Lisa A. , Wefel, Jeffrey S. , Gilbert, Mark R. , Robinson, Clifford G. , Benzinger, Tammie L S , Tomé, Wolfgang A. , Armstrong, Terri S. , Bruner, Deborah Watkins , Kundapur, Vijayananda , Stea, Baldassarre , Laack, Nadia N. , Kruser, Tim J. , Shi, Wenyin , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi172-vi172

10.1093/neuonc/noy148.716 Get It

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma
Koehler, Jennifer W. , Miller, Andrew D. , Miller, C. Ryan , Aldape, Kenneth , Beck, Jessica A. , Corps, Kara N. , Frank, Chad , O’Sullivan, M. Gerard , Rissi, Daniel R. , Simpson, R. Mark , Woolard, Kevin , Shih, Joanna H. , Mazcko, Christina , O’Sullivan, M. Gerard , O'Sullivan, M Gerard , Porter, Brian F. , Brat, Daniel J. , Cornax, Ingrid , Giannini, Caterina , Horbinski, Craig , Huse, Jason T. , Gilbert, Mark R. , LeBlanc, Amy Kathleen

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | September 19, 2018 | Volume: 77 | Issue: 11 | Pages: 1039-1054

10.1093/jnen/nly085 | PMID 30239918 Get It

Case-based review: ependymomas in adults
Cachia, David , Lowe, Stephen , Andersen, Samuel, Olar, Adriana , Frankel, Bruce, Johnson, Derek R. , Kaufmann, Timothy J. , Cooper, Samuel Lewis , Gilbert, Mark R.

Mayo Clinic

Neuro-Oncology Practice | July 25, 2018 | Volume: 5 | Issue: 3 | Pages: 142-153

10.1093/nop/npy026 | PMID 31386035 Get It

Abstract Ependymomas are rare primary central nervous system (CNS) tumors in adults. They occur most commonly in the spinal cord, and have classically been graded histologically into World Health Organization (WHO) grades I, II, or III based on the level of anaplasia. Recent data are showing that genetic heterogeneity occurs within the same histological subgroup and that ependymomas arising from different CNS locations have different molecular signatures. This has renewed interest in developing targeting therapies based on molecular profiles especially given the variable outcomes with radiation and the poor results with cytotoxic agents. In this paper, we present the case of a 46-year-old woman with a classic presentation of spinal cord ependymoma and discuss the current histopathological and molecular classification for ependymomas as well as current guidelines for patient management.
Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes
Hall, William A. , Pugh, Stephanie L. , Armstrong, Terri S. , Brachman, David, Werner‐Wasik, Maria, Wendland, Merideth M, Brown, Paul D. , Chao, Samuel T. , Roof, Kevin S. , Robins, H. Ian, Curran, Walter J. , Movsas, Benjamin , Armstrong, Terri S , Wefel, Jeffrey S. , Gilbert, Mark R. , Mehta, Minesh P.

Mayo Clinic

Neurosurgery | February 15, 2018 | Volume: 84 | Issue: 1 | Pages: 66-76

10.1093/neuros/nyy003 | PMID 29618054 Get It

Abstract BACKGROUND The influence of subtotal resection (STR) on neurocognitive function (NCF), quality of life, and symptom burden in glioblastoma is unknown. If bevacizumab preferentially benefits patients with STR is unknown. OBJECTIVE To examine these uncertainties. METHODS NCF and patient reported outcomes (PRO) were prospectively collected in NRG Oncology RTOG 0525 and 0825. Changes in NCF and PRO measures from baseline to prespecified times were examined by Wilcoxon test, and mixed effects longitudinal modeling, to assess differences between patients who received STR vs gross-total resection. Changes were also compared among STR patients on 0825 receiving placebo vs bevacizumab to assess for a preferential therapeutic effect. Overall survival between STR and gross-total resection patients was compared using the Kaplan–Meier method. RESULTS A total of 427 patients were eligible with STR present in 37%. At baseline, patients with STR had worse NCF, worse MD Anderson Symptom Inventory Brain Tumor Neurological Factor ratings ( P = .004), and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire ( P = .002). Longitudinal multivariate analysis associated STR with worse NCF (Hopkins Verbal Learning Test–Revised Delayed Recognition [ P = .048], Trail Making Test Part A [ P = .035], and Controlled Oral Word Association [ P = .049]). One hundred eighty-three STR patients from 0825 were analyzed (89 bevacizumab, 94 placebo); bevacizumab failed to demonstrate improvement in select NCF or PRO measures. CONCLUSION STR patients had worse NCF and PROs before therapy. During adjuvant therapy, STR patients had worse objective NCF, despite accounting for tumor location. STR did not result in a detriment to OS. The addition of bevacizumab did not preferentially improve PRO or NCF outcomes in STR patients.
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database
Blumenthal, Deborah T. , Won, Minhee , Brown, Paul D. , Bokstein, Felix , Brachman, David, Werner‐Wasik, Maria, Hunter, G.K., Valeinis, Egils , Hopkins, Kirsten, Souhami, Luís, Howard, Steven , Lieberman, Frank S. , Shrieve, Dennis C. , Wendland, Merideth M, Robinson, Clifford G. , Corn, Benjamin W. , Robinson, Clifford , Mehta, Minesh P. , Gilbert, Mark R. , Zhang, Peixin

Mayo Clinic

Neuro-Oncology | February 13, 2018 | Volume: 20 | Issue: 7 | Pages: 966-974

10.1093/neuonc/noy017 | PMID 29462493 Get It

Association of genetic variants with fatigue in patients with malignant glioma
Armstrong, Terri S. , Vera, Elizabeth , Zhou, Renke, Acquaye, Alvina , Sullaway, Catherine, Berger, Ann M. , Mahajan, Anita , Bondy, Melissa L. , Scheurer, Michael E. , Armstrong, Terri S , Breton, Ghislaı̀n , Wefel, Jeffrey S. , Gilbert, Mark R.

Mayo Clinic

Neuro-Oncology Practice | September 19, 2017 | Volume: 5 | Issue: 2 | Pages: 122-128

10.1093/nop/npx020 | PMID 31386001 Get It

AbstractBackgroundFatigue is a consistently reported, severe symptom among patients with gliomas throughout the disease trajectory. Genomic pathways associated with fatigue in glioma patients have yet to be identified.MethodsClinical factors (performance status, tumor details, age, gender) were collected by chart review on glioma patients with fatigue (“I have lack of energy” on Functional Assessment of Cancer Therapy-Brain), as well as available genotyping data. Candidate genes in clock and inflammatory pathways were identified from a literature review, of which 50 single nucleotide polymorphisms (SNPs) in 7 genes were available. Clinical factors and SNPs identified by univariate analyses were included in a multivariate model for moderate-severe fatigue.ResultsThe study included 176 patients (median age = 47 years, 67% males). Moderate-severe fatigue was reported by 43%. Results from multivariate analysis revealed poor performance status and 2 SNPs were associated with fatigue severity. Moderate-severe fatigue was more common in patients with poor performance status (OR = 3.52, P < .01). For each additional copy of the minor allele in rs934945 (PER2) the odds of fatigue decreased (OR = 0.51, P < .05). For each additional copy of the minor allele in rs922270 (ARTNL2) the odds of fatigue increased (OR = 2.38, P < .01). Both of these genes are important in the circadian clock pathway, which has been implicated in diurnal preference, and duration and quality of sleep. No genes in the inflammatory pathway were associated with fatigue in the current study.ConclusionsIdentifying patients at highest risk for fatigue during treatment allows for improved clinical monitoring and enrichment of patient selection for clinical trials.